Pulmonary Drug Delivery Systems Market Size Will Reach US$92.4


Ottawa, April 06, 2022 (GLOBE NEWSWIRE) — The world pulmonary drug delivery systems market is mainly driven by the increasing prevalence of various lung diseases such as asthma, chronic obstructive pulmonary disease and allergic rhinitis. The increased awareness of the population in the control and management of pulmonary diseases is fueling the demand for pulmonary drug delivery systems across the world. Rising levels of pollution due to rapid industrialization, rapid urbanization, increased prevalence of smoking, and changing lifestyles are resulting in an increasing number of patients suffering from different lung diseases.

Get the Sample Report Pages @ https://www.precedenceresearch.com/sample/1502

According to the World Health Organization, about 90% of the population breathe polluted air and about 7 million people die each year due to indoor and outdoor pollution. Moreover, the presence of various key market players and their innovative product launches are impacting the growing demand for pulmonary drug delivery devices. For example, in April 2019, Glenmark Pharmaceuticals Ltd. introduced the latest inhalers – a metered inhaler named Soprobec and another breath-actuated inhaler named Stalpex.

Report scope Details
Market size in 2021 $51.87 billion
CAGR 6.6% from 2021 to 2030
By product
  • Dry powder inhalers
  • Nebulizers
  • Metered dose inhalers
  • Accessories
By indication
  • COPD
  • Asthma
  • Cystic fibrosis
  • Allergic rhinitis
  • Others
By distribution channel
  • Retail pharmacy
  • Hospital pharmacy
  • E-commerce
By geography
  • North America
  • Europe
  • Asia Pacific
  • Latin America
  • Middle East and Africa (MEA)

Report Highlights

  • Based on the product, metered dose inhaler segment dominated the market in 2020. Greater product acceptance and rising prevalence of lung diseases fueled the growth of this segment. Additionally, innovative product launches have further boosted the growth of the market.
  • Based on indication, asthma accounted for the largest market share in 2020. According to the WHO, asthma affects both adults and children. Changing lifestyle, rapid urbanization and prolonged exposure to harmful particles in the air are the main reasons for the increase in the prevalence of asthma. Increased demand for pulmonary drug delivery systems for the treatment of asthma has driven the growth of this segment.
  • Based on distribution channel, e-commerce is estimated to be the most opportunistic segment during the forecast period. This is attributed to the increasing penetration of online pharmacies owing to the growing adoption of smartphones and the internet across the globe.

Ask here for more customization study @ https://www.precedenceresearch.com/customization/1502

Regional overview

North America dominated the global pulmonary drug delivery systems market in 2020. This is attributed to the increased demand for pulmonary drug delivery devices owing to the increasing prevalence of various lung diseases. According to the Asthma and Allergy Foundation of America, approximately 25 million people had asthma in 2018 in the United States. Additionally, according to the American Lung Association, approximately 16.4 million people in the United States have been diagnosed with some type of COPD such as emphysema, chronic bronchitis, and COPD. Rising healthcare expenditures, increased penetration of pharmacies and better access to healthcare facilities are the major factors driving the demand for pulmonary drug delivery systems in North America.

Asia Pacific is expected to be the fastest growing market over the forecast period. This is attributed to the increasing levels of air pollution in the region. Additionally, changing consumer lifestyles and rapid industrialization are leading to an alarming increase in the prevalence of respiratory and lung diseases. According to the World Health Organization, around 80% of deaths from COPD occur in low- and middle-income countries. Hence, the presence of huge population and rising mortality rates are expected to drive the market growth in Asia Pacific.

Market dynamics

Driver

Increased prevalence of lung disease

According to the World Health Organization, around 65 million people worldwide suffer from COPD and around 3 million die from it every year. Around 334 million people suffer from asthma and around 14% of children worldwide are affected. Rising mortality rates and increased awareness of lung diseases are expected to drive the market growth over the forecast period.

Detention

Strict government regulations

The strict regulatory scenario and regulatory requirements of drug delivery systems pose a challenge for market players, as pulmonary drug delivery systems are a combination of drug and device. Therefore, it is regulated under new provisions by the government.

Opportunity

New product launches

Philips launched a drinking mesh nebulizer named InnoSpire Go in 2018. It is a portable, handheld, small size and lightweight nebulizer that can deliver medication in just a few minutes. Additionally, Lupine introduced Adhero in 2019. It is a device that follows the pattern of use of metered dose inhalers by COPD patients. Therefore, frequent product launches with new and innovative features are expected to drive growth in the future.

Challenge

Lack of access to health facilities

There is a lack of adequate health infrastructure and lack of access to basic health facilities in developing and underdeveloped markets. Most people go undiagnosed and untreated, which can hamper the growth of the market.

Some of the major players in the Global Pulmonary Drug Delivery Systems Market include:

  • GlaxoSmithKline PLC
  • BoehringerIngelheim GmbH
  • AstraZeneca PLC
  • Teva Pharmaceutical Industries Ltd.
  • Philips Respironics
  • 3M Health
  • PARI GmbH
  • F. Hoffmann-La Roche SA
  • Gilbert Technologies
  • Omron Healthcare, Inc.

Click here to View full report table of contents

Buy this Premium Research Report @ https://www.precedenceresearch.com/checkout/1502

You can place an order or ask any questions, please feel free to contact at [email protected] | +1 9197 992 333

About Us

Precedence Research is a global market research and consulting organization. We provide an unparalleled nature of offering to our customers located all over the world across industry verticals. Precedence Research has expertise in providing in-depth market intelligence as well as market insights to our clients spread across various businesses. We are obligated to serve our diverse customer base in medical services, healthcare, innovation, next-generation technology, semiconductor, chemical, automotive, aerospace and of defence, among the various companies present in the world.

For the latest update, follow us:

https://www.linkedin.com/company/precedence-research/

https://www.facebook.com/precedenceresearch/

https://twitter.com/Precedence_R

Previous UMass students react to mask mandate lifting and pandemic two-year mark - Massachusetts Daily Collegian
Next Online lending platforms offering loans at extortionate rates: HC asks RBI to file status report